Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valproate semisodium - Abbott Laboratories

Next Previous
Drug Profile

Valproate semisodium - Abbott Laboratories

Alternative Names: [14C]-Sodium Valproate; Depakote; Depakote ER; Divalproex; Divalproex sodium; Divalproex sodium DR 500mg tablets - Abbott Laboratories; Epival; Epival ER; LA40220

Latest Information Update: 21 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Sanofi
  • Class Antiepileptic drugs; Antimanics; Antimigraines; Pentanoic acids; Small molecules
  • Mechanism of Action GABA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Epilepsy; Migraine
  • Phase III Dementia

Most Recent Events

  • 02 Nov 2018 Phase-I clinical trials in Epilepsy (In volunteers) in United Kingdom (PO) (NCT03681158)
  • 28 Sep 2018 Sanofi plans a phase I BEX15316 trial for Epilepsy (In volunteers) in Canada and USA (PO) in November 2018 (NCT03681158) (EudraCT2017-004987-36)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top